Study: ObamaCare Would Double or Triple Premiums for Most

Bend the cost-curve so that those paying for insurance will pay more, to cover those currently uninsured.

Of course. Of course. There are no magic beans here. If you're insuring a family of four, guess what? You're getting a new family member or two whose premiums you will have to cover.

The best sort of family member: One you've never met and who then doesn't have to be invited to weddings and won't get drunk at Thanksgiving.

Take Ohio, where a young, healthy 25-year-old living in Columbus can purchase insurance from WellPoint today for about $52 per month in the individual market. WellPoint's actuaries calculate the bill will rise to $79 because Democrats are going to require it to issue policies to anyone who applies, even if they've waited until they're sick to buy insurance. Then they'll also require the company to charge everyone nearly the same rate, bringing the premium to $134. Add in an extra $17, since Democrats will require higher benefit levels, and a share of the new health industry taxes ($6), and monthly premiums have risen to $157, a 199% boost.

Meanwhile, a 40-year-old husband and wife with two kids would see their premiums jump by 122%—to $737 from $332—while a small business with eight employees in Franklin County would see premiums climb by 86%. It's true that the family or the individual might qualify for subsidies if their incomes are low enough, but the business wouldn't qualify under the Senate Finance bill WellPoint examined. And even if there are subsidies, the new costs the bill creates don't vaporize. They're merely transferred to taxpayers nationwide—or financed with deficits, which will be financed eventually with higher taxes.

...

A family of four with average health in those same cities would all face cost increases of 122% buying insurance on the individual market. And it's important to understand that these are merely the new costs created by ObamaCare—not including the natural increases in medical costs over time from new therapies and the like.